Business Wire

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA), June 9-12 in Vienna, Austria. Takeda’s latest research in oncology focuses on enhancing and improving patient care while exploring novel approaches for patients with limited treatment options.

Data presentations span a range of cancers, including lymphoma, leukemia, multiple myeloma and non-small cell lung cancer, including early insights into investigational therapies that leverage the innate immune system.

“Our data at this spring’s medical congresses are indicative of our quest to outsmart cancer and our ability to work collaboratively with partners to further our research capabilities,” said Christopher Arendt, Ph.D., Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “In addition to sharing data on currently approved therapies, we look forward to presenting early findings from our innate immunity clinical programs – many of which are exploring novel mechanisms of action – that we believe have the power to advance the field of oncology and recast current standards of care.”

A full list of company-sponsored abstracts are available for ASCO and EHA.

Takeda’s Commitment to Oncology

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

Oncology U.S. and International Media
Lauren Padovan
lauren.padovan@takeda.com
+1 (215) 859-2605

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China4.7.2022 14:30:00 EEST | Press release

A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific COVID-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunization strategy. This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005146/en/ [From right to left] Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine of The University of Hong Kong; Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong; Ms. Cheryl Law, International

BearingPoint Appoints 19 New Partners Across Europe4.7.2022 10:58:00 EEST | Press release

Management and technology consultancy BearingPoint announced today that it has appointed 19 new Partners across Europe. 14 Partners have been internally promoted, and five Partners joined BearingPoint from outside the firm. The appointments underline the firm’s ongoing success and growth and the ambitions defined in its Strategy 2025: putting people in the center, outperforming the market every year, and being in the top three in chosen areas of expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005035/en/ Kiumars Hamidian, Managing Partner BearingPoint. (Photo: Business Wire) Kiumars Hamidian, Managing Partner BearingPoint, said: “It is a real pleasure that we were able to promote internally 14 new Partners to our Partner-led firm. All of them have reached this important milestone based on their exceptional abilities, deep industry expertise and outstanding commitment to serving our clients. In addition to our

VOOPOO Unveils 3 New Products, Telling Story of Its 8-year Entrepreneurship Journey in 30 Minutes4.7.2022 10:15:00 EEST | Press release

VOOPOO’s 2022 "More Than Infinity" virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connection between the “infinity symbol” and the brand spirit and demonstrating its commitment to creating infinite new possibilities using technology in 3 chapters. Meanwhile, the event was highlighted by 3 POD products featuring VOOPOO’s most cutting-edge technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005586/en/ Infinite innovation: The new product launch, backed by atomization platforms and chip development, manifests VOOPOO’s R&D strength. (Graphic: Business Wire) A very important theme at the virtual event was telling the growth story of VOOPOO since its founding 8 years ago. Evolving from an atomization chip solution provider to today’s industry leader of open electronic atomization, VOOPOO has driven the

AGILA Pet Insurance becomes part of JAB Backed Pinnacle Pet Group, to create a Leading Pan-European Pet Insurance Platform4.7.2022 10:00:00 EEST | Press release

JAB Holding Company ("JAB") and WERTGARANTIE Group today announced a strategic partnership whereby JAB's European pet insurance platform, Pinnacle Pet Group ("PPG") will acquire 100% of the shares in AGILA Tierversicherung AG (“AGILA”), the German market leader in pet insurance, from the WERTGARANTIE Group. In return, the WERTGARANTIE Group will become an investor in PPG. The transaction is expected to close in Q4 2022, subject to customary closing conditions, including regulatory approvals. The parties have agreed not to disclose the financial details of the transaction. With JAB’s support, PPG will be built into a leading Pan-European platform for animal insurance through strategic investments and organic growth. The WERTGARANTIE Group will also continue to support PPG successful German activities as a relevant shareholder. AGILA will be an essential component of PPG's expansion. All employees at the Hanover headquarters will join the platform and will play a key role in PPG’s expans

Port Decarbonization: the First High-powered Hydrogen Barge for the Electrification of Ships at Berth4.7.2022 09:00:00 EEST | Press release

Hydrogène de France (“HDF Energy”) – Euronext Paris: HDF – and its partners of the ELEMANTA H2 project announce the signature of an MoU to deploy mobile solutions providing, from green or low-carbon hydrogen, cold ironing services complementing the electrical grid, for container ships, cruise ships or tankers. ELEMANTA H2 will also enable hydrogen bunkering to meet the refueling needs of future hydrogen ships. Maritime transport accounted for 13.5% of European total greenhouse gas emissions in 2018. In order to reach the European objective of reducing greenhouse gas emissions by 55% by 2030, the sector must accelerate its energy transition. ELEMANTA H2 aims to contribute to the decarbonization of port activities. The partners have identified the Port of Rouen and the Rubis Terminal location as a pioneer site because of its strategic position close to Paris. With the support of Normandie Energies and the port operator HAROPA, a demonstration barge will embed a high-power hydrogen fuel c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom